Vesilute (Vesilut) Peptide

Vesilute, also known as Vesilut and often abbreviated as ED, is a synthetic dipeptide composed of L-glutamic acid and L-aspartic acid (Glu-Asp). With a molecular formula of C9H14N2O7 and a molecular weight of 262.22 g/mol, this short peptide belongs to the family of Khavinson short peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. The compound has garnered research interest due to its position within the broader class of ultrashort peptides believed to influence tissue-specific gene expression and cellular homeostasis.

The Glu-Asp sequence itself is not an arbitrary construct — it forms a core motif embedded within the tetrapeptide Prostamax (Lys-Glu-Asp-Pro), a peptide historically associated with prostate tissue research within the Khavinson bioregulator framework. This structural relationship has led investigators to explore whether Vesilute may retain a subset of the biological activities attributed to its parent tetrapeptide, particularly those relating to genitourinary tissue signaling. The dipeptide is one of several ultrashort bioregulators (di-, tri-, and tetrapeptides) proposed by Khavinson and colleagues as templates for understanding peptide-DNA interactions.

Research significance for Vesilute lies primarily in its use as a model compound within the peptide bioregulator hypothesis, which posits that short peptides can penetrate cellular and nuclear membranes to interact directly with promoter regions of DNA, thereby modulating tissue-specific gene expression. While the peer-reviewed literature on Vesilute itself is more limited than for widely studied Khavinson peptides such as Epithalon (Ala-Glu-Asp-Gly) or Thymalin, the compound is frequently discussed in the context of urinary and prostatic tissue regulation studies conducted primarily by Russian research groups.

What distinguishes Vesilute from other short peptide bioregulators is its structural minimalism. As a dipeptide, it represents one of the shortest functional units within the Khavinson framework, providing investigators with a compact scaffold to probe structure-activity relationships. Comparative studies suggest that even di- and tripeptides retain the capacity to bind specific DNA sequences, and Vesilute is often used alongside related dipeptides (such as Lys-Glu, the Epithalon precursor motif) to dissect which residues are essential for observed bioregulatory effects. The compound is supplied as a lyophilized powder for laboratory research applications only.

The proposed mechanism of action for Vesilute (Glu-Asp) is grounded in the peptide bioregulator hypothesis originally advanced by Khavinson and colleagues. Under this framework, ultrashort peptides such as Vesilute are believed to act through several complementary pathways involving direct nucleic acid interaction, epigenetic modulation, and tissue-specific gene expression regulation.

Direct Peptide-DNA Interaction: Molecular modeling and biophysical studies of Khavinson-family peptides suggest that short peptides can interact with specific base-pair sequences in double-stranded DNA via hydrogen bonding and electrostatic contacts within the major groove. Glutamic and aspartic acid residues, both acidic amino acids bearing carboxylic side chains, are proposed to form sequence-specific hydrogen bonds with guanine-cytosine and adenine-thymine pairs. This selective binding is hypothesized to influence promoter accessibility for specific genes involved in cellular differentiation and homeostasis.

Epigenetic Modulation: Short peptide bioregulators have been reported in preclinical studies to influence DNA methylation patterns and histone modifications, thereby affecting long-term gene expression programs. Vesilute, sharing the acidic Glu-Asp core, is postulated to participate in similar epigenetic effects, though direct experimental confirmation specific to this dipeptide remains limited compared to longer peptides like Epithalon.

Tissue-Specific Gene Expression: Because Vesilute derives its sequence from the prostatic tetrapeptide Prostamax, research has focused on whether the dipeptide can independently modulate genes associated with prostatic and urinary tract epithelial cells. Preclinical work with related bioregulators has documented shifts in the expression of genes governing proliferation, apoptosis, and inflammation in target tissues, with dose-dependent effects observed at nanomolar to micromolar concentrations.

Antioxidant and Cytoprotective Effects: The free carboxyl groups of Glu and Asp may also contribute to weak metal-chelating and antioxidant activity, a property observed for several small acidic peptides. Under this pathway, Vesilute could reduce oxidative stress markers in cellular models, though this represents a secondary rather than primary proposed mechanism.

Comparison to Related Bioregulators: Vesilute differs mechanistically from tetrapeptides like Epithalon (which is more strongly associated with telomerase activation) and from tripeptides like KE (Lys-Glu, sometimes called Vilon), which has been more extensively studied in immune contexts. Vesilute represents a simpler probe of the general Khavinson hypothesis: whether even minimal peptide sequences can retain sequence-specific regulatory activity. Research using Vesilute typically employs comparator peptides to distinguish generic amino-acid-supplementation effects from truly sequence-specific bioregulatory action.

The dipeptide Vesilute is characterized by its highly acidic nature, owing to two carboxylate-bearing side chains contributed by both glutamic and aspartic acid residues. This gives the molecule strong aqueous solubility across neutral and mildly alkaline pH but limits solubility in nonpolar solvents. The compound lacks disulfide bonds, aromatic residues, or oxidation-sensitive side chains (such as methionine or cysteine), making it comparatively stable to standard laboratory handling. Its low molecular weight and small size distinguish it from most peptide bioregulators supplied for research and result in relatively simple purification and characterization profiles. Structural verification is typically performed by mass spectrometry and reverse-phase HPLC.

Vesilute (Glu-Asp) is supplied as a lyophilized white powder. As a small, highly polar dicarboxylic dipeptide, it is readily soluble in aqueous buffers and does not require organic co-solvents for reconstitution. Standard aseptic technique should be observed throughout, and all handling should be performed in a certified laboratory setting by trained personnel using appropriate PPE.

Recommended Reconstitution Protocol

1. Equilibrate the vial: allow the sealed lyophilized vial to reach room temperature (approximately 15-20 minutes) before opening to prevent moisture condensation on the powder.
2. Select diluent: use bacteriostatic water for injection (0.9% benzyl alcohol) for solutions intended to be stored for more than 24 hours, or sterile water / phosphate-buffered saline (pH 7.2-7.4) for immediate-use preparations.
3. Calculate concentration: for a 20 mg vial, adding 2 mL of diluent yields a 10 mg/mL stock solution. For a 5 mg/mL working solution, add 4 mL.
4. Add diluent slowly: introduce the diluent down the inner wall of the vial rather than directly onto the peptide cake to minimize localized shear.
5. Dissolve gently: swirl or roll the vial between the palms until the solution is clear. Do not shake or vortex vigorously, as mechanical agitation can promote foaming and denaturation of the peptide.
6. Inspect and aliquot: the resulting solution should be clear, colorless, and free of visible particulates. For extended studies, prepare single-use aliquots to avoid repeated freeze-thaw cycles.

Compound-Specific Handling Notes

• pH sensitivity: Glu-Asp is a dicarboxylic dipeptide with two acidic side chains; neutral to slightly acidic aqueous vehicles (pH 5-7) are generally preferred. Strongly alkaline conditions may accelerate hydrolysis.
• No disulfide bonds or methionine: Vesilute contains only glutamic acid and aspartic acid, so it is not susceptible to disulfide scrambling or methionine oxidation. Standard antioxidants are not required.
• Filtration: if terminal sterile filtration is required, use a low-protein-binding 0.22 µm PVDF or PES filter and prime the filter with a small volume before collecting the working solution.
• Labeling: record concentration, diluent, date of reconstitution, and initials on the vial; segregate from clinical-use materials in accordance with institutional research policy.

All handling and downstream use of Vesilute must comply with local biosafety and research-use regulations. This product is supplied strictly for in vitro and preclinical laboratory research and is not intended for human or veterinary use.

Proper storage is critical to preserving the chemical integrity and biological activity of Vesilute (Glu-Asp). Although the dipeptide is chemically simpler than larger regulatory peptides, standard cold-chain and light-protection practices should be followed to maximize shelf life and ensure reproducible experimental results.

Lyophilized Powder

• Long-term storage: store the sealed lyophilized vial at -20°C in a manual-defrost freezer. Under these conditions, the peptide is expected to remain stable for at least 24 months from the date of manufacture.
• Short-term storage: refrigeration at 2-8°C is acceptable for up to 30 days prior to use.
• Transit: brief exposure to ambient temperature during shipping (up to 5-7 days) does not appreciably degrade the lyophilized peptide, as demonstrated for other Khavinson-class dipeptides.
• Environmental controls: keep vials in the original packaging, protected from direct light and moisture. A desiccant-containing secondary container is recommended for long-term freezer storage.

Reconstituted Solutions

• In bacteriostatic water: stable at 2-8°C for up to 28 days when prepared with sterile technique.
• In sterile water or PBS: use within 24-48 hours if refrigerated; longer-term storage requires aliquoting and freezing at -20°C or -80°C.
• Freeze-thaw: minimize freeze-thaw cycles by preparing single-use aliquots. Repeated cycling may promote peptide aggregation and gradual loss of activity even for small peptides.

Stability-Relevant Chemistry

Vesilute contains no cysteine (no disulfide bridges), no methionine (no oxidation-prone thioether), no tryptophan (no photo-oxidation), and no N-terminal glutamine (no pyroglutamate formation). The primary chemical liabilities are potential slow hydrolysis of the peptide bond under strongly acidic or alkaline aqueous conditions and hygroscopic uptake of moisture by the lyophilizate. Both risks are effectively mitigated by frozen storage of the sealed vial and by neutral-pH aqueous vehicles for working solutions.

Quality Assurance

Each lot of Vesilute supplied by AminoCore Research is accompanied by a third-party certificate of analysis reporting HPLC purity, mass-spectrometric identity confirmation, and appearance. Investigators are encouraged to retain the COA with their laboratory records and, for long-term studies, to periodically re-verify purity by HPLC on stored material.